Amylyx Pharmaceuticals, Inc. (AMLX) vs Celcuity Inc. (CELC)

A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Celcuity Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AMLX

Amylyx Pharmaceuticals, Inc.

$3.09B

$27.82HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

CELC

Celcuity Inc.

$3.49B

$71.49HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

Total return — AMLX vs CELC

growth of $100 · dividends reinvested · last 5y

AMLX +53.7% (+9.0%/yr)CELC +481.1% (+42.2%/yr)CELC compounded faster over this window

AMLX CELC

AMLX vs CELC: by the numbers

•CELC is the larger company ($3.49B vs $3.09B market cap).

Metrics side by side

Valuation

Metric	AMLX	CELC
P/B ratio	12.93	N/A

Profitability

Metric	AMLX	CELC
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-63.59%	N/A
ROIC	-66.60%	-28.15%

Growth (annualized)

Metric	AMLX	CELC
Total return CAGR (5Y)	N/A	34.40%

Go deeper

Full AMLX analysis Full CELC analysis Interactive comparison tool

Dig into the metrics

Amylyx Pharmaceuticals ROE Celcuity ROE Amylyx Pharmaceuticals operating margin Celcuity operating margin Amylyx Pharmaceuticals revenue growth Celcuity revenue growth Amylyx Pharmaceuticals free cash flow Celcuity free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.